SPHK1 and prostate cancer: Since SKI-178 can block both SphK1 and SphK2, it was not surprising to show that SKI-178-induced SphK inhibition and prostate cancer cell death were significantly more potent than the SphK1 inhibitor PF-543 and the SphK2 inhibitor ABC294640.